APA (7th ed.) Citation

Feist, E., Fatenejad, S., Grishin, S., Korneva, E., Luggen, M., Nasonov, E., . . . Fleischmann, R. (2023). Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: Efficacy and safety results of a randomised controlled phase III study. IMA-PRESS LLC.

Chicago Style (17th ed.) Citation

Feist, E., S. Fatenejad, S. Grishin, E. Korneva, M.E Luggen, E. Nasonov, M. Samsonov, J.S Smolen, and R.M Fleischmann. Olokizumab, a Monoclonal Antibody Against Interleukin-6, in Combination with Methotrexate in Patients with Rheumatoid Arthritis Inadequately Controlled by Tumour Necrosis Factor Inhibitor Therapy: Efficacy and Safety Results of a Randomised Controlled Phase III Study. IMA-PRESS LLC, 2023.

MLA (9th ed.) Citation

Feist, E., et al. Olokizumab, a Monoclonal Antibody Against Interleukin-6, in Combination with Methotrexate in Patients with Rheumatoid Arthritis Inadequately Controlled by Tumour Necrosis Factor Inhibitor Therapy: Efficacy and Safety Results of a Randomised Controlled Phase III Study. IMA-PRESS LLC, 2023.